Journal Article

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Pricop, Luminita, Ritchlin, Christopher T., McInnes, Iain B., Mease, Philip J., Blanco, Ricardo, Dokoupilova, Eva, Mpofu, Shephard, Rahman, Proton, Andersson, Mats, Nash, Peter, Kajekar, Radhika

2018

Overview

Background The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study ( ClinicalTrials.gov NCT01989468). Methods Patients (≥ 18 years of age; N = 414) with active PsA were randomized 1:1:1 to subcutaneous (s.c.) secukinumab 300 mg, 150 mg, or placebo at baseline, weeks 1, 2, 3, and 4, and every 4 weeks thereafter. Per clinical response, placebo-treated patients were re-randomized to s.c. secukinumab 300 or 150 mg at week 16 (nonresponders) or week 24 (responders) and stratified at randomization by prior anti-tumor necrosis factor (TNF) therapy (anti-TNF-naïve, 68.1%; intolerant/inadequate response (anti-TNF-IR), 31.9%). The primary endpoint was the proportion of patients achieving at least 20% improvement in American College of Rheumatology response criteria (ACR20) at week 24. Autoinjector usability was evaluated by Self-Injection Assessment Questionnaire (SIAQ). Results Overall, 92.1% (300 mg), 91.3% (150 mg), and 93.4% (placebo) of patients completed 24 weeks, and 84.9% (300 mg) and 79.7% (150 mg) completed 52 weeks. In the overall population (combined anti-TNF-naïve and anti-TNF-IR), ACR20 response rate at week 24 was significantly higher in secukinumab groups (300 mg, 48.2% ( p < 0.0001); 150 mg, 42% ( p < 0.0001); placebo, 16.1%) and was sustained through 52 weeks. SIAQ results showed that more than 93% of patients were satisfied/very satisfied with autoinjector usage. Secukinumab was well tolerated with no new or unexpected safety signals reported. Conclusions Secukinumab provided sustained improvements in signs and symptoms in active PsA patients through 52 weeks. High acceptability of autoinjector was observed. The safety profile was consistent with that reported previously. Trial registration ClinicalTrials.gov NCT01989468 . Registered 21 November 2013. EudraCT 2013–004002-25 . Registered 17 December 2013.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Adult / Antibodies, Monoclonal - administration & dosage / Antibodies, Monoclonal - adverse effects / Antibodies, Monoclonal, Humanized / Arthritis, Psoriatic - diagnosis / Arthritis, Psoriatic - drug therapy / Autoinjector / Double-Blind Method / Drug Delivery Systems - adverse effects / Drug Delivery Systems - methods / Drug therapy / Female / FUTURE 3 study / Headache - chemically induced / Humans / Injections, Subcutaneous / Interleukin-17a / Male / Medicine / Medicine & Public Health / Middle Aged / Nasopharyngitis - chemically induced / Orthopedics / Patient outcomes / Psoriatic arthritis / Research Article / Rheumatology / Secukinumab / Self Administration / Treatment Outcome